Your browser doesn't support javascript.
loading
Phase II study of carfilzomib and dexamethasone therapy for newly diagnosed multiple myeloma.
Forsberg, Peter A; Rossi, Adriana C; Boyer, Angelique; Tegnestam, Linda; Pearse, Roger N; Perry, Arthur; Pekle, Karen A; Jayabalan, David; Ely, Scott; Boussi, Leora; Sherbenou, Daniel W; Williams, Colt; Allan, John N; Coleman, Morton; Niesvizky, Ruben; Mark, Tomer M.
Afiliação
  • Forsberg PA; Department of Medicine, Division of Hematology, University of Colorado School of Medicine, Aurora, Colorado.
  • Rossi AC; Department of Medicine, Division of Hematology/Oncology, Weill Medical College of Cornell University, New York Presbyterian Hospital, New York, New York.
  • Boyer A; Department of Medicine, Division of Hematology/Oncology, Weill Medical College of Cornell University, New York Presbyterian Hospital, New York, New York.
  • Tegnestam L; Department of Medicine, Division of Hematology/Oncology, Weill Medical College of Cornell University, New York Presbyterian Hospital, New York, New York.
  • Pearse RN; Department of Medicine, Division of Hematology/Oncology, Weill Medical College of Cornell University, New York Presbyterian Hospital, New York, New York.
  • Perry A; Department of Medicine, Division of Hematology/Oncology, Weill Medical College of Cornell University, New York Presbyterian Hospital, New York, New York.
  • Pekle KA; Department of Medicine, Division of Hematology/Oncology, Weill Medical College of Cornell University, New York Presbyterian Hospital, New York, New York.
  • Jayabalan D; Department of Medicine, Division of Hematology/Oncology, Weill Medical College of Cornell University, New York Presbyterian Hospital, New York, New York.
  • Ely S; Department of Pathology, Bristol-Myers Squibb, New York, New York.
  • Boussi L; New York Medical College, Valhalla, New York.
  • Sherbenou DW; Department of Medicine, Division of Hematology, University of Colorado School of Medicine, Aurora, Colorado.
  • Williams C; Department of Medicine, Division of Hematology, University of Colorado School of Medicine, Aurora, Colorado.
  • Allan JN; Department of Medicine, Division of Hematology/Oncology, Weill Medical College of Cornell University, New York Presbyterian Hospital, New York, New York.
  • Coleman M; Department of Medicine, Division of Hematology/Oncology, Weill Medical College of Cornell University, New York Presbyterian Hospital, New York, New York.
  • Niesvizky R; Department of Medicine, Division of Hematology/Oncology, Weill Medical College of Cornell University, New York Presbyterian Hospital, New York, New York.
  • Mark TM; Department of Medicine, Division of Hematology, University of Colorado School of Medicine, Aurora, Colorado.
Am J Hematol ; 94(5): 539-545, 2019 05.
Article em En | MEDLINE | ID: mdl-30740766
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Oligopeptídeos / Dexametasona / Protocolos de Quimioterapia Combinada Antineoplásica / Mieloma Múltiplo Tipo de estudo: Diagnostic_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Am J Hematol Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Oligopeptídeos / Dexametasona / Protocolos de Quimioterapia Combinada Antineoplásica / Mieloma Múltiplo Tipo de estudo: Diagnostic_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Am J Hematol Ano de publicação: 2019 Tipo de documento: Article